Full-Time

Principal Medical Device Security Engineer

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$102k - $177.1k/yr

New Mexico, USA + 48 more

More locations: Washington, USA | Kansas, USA | Pennsylvania, USA | North Dakota, USA | Oregon, USA | Delaware, USA | Iowa, USA | California, USA | Vermont, USA | Wyoming, USA | Texas, USA | Montana, USA | Jackson Township, NJ, USA | Florida, USA | Waterbury, CT, USA | Nevada, USA | South Carolina, USA | South Dakota, USA | Georgia, USA | Arizona, USA | Concord, NH, USA | Mississippi, USA | Tennessee, USA | Virginia, USA | Arkansas, USA | Minnesota, USA | Nebraska, USA | Rhode Island, USA | Utah, USA | Kentucky, USA | West Virginia, USA | New York, NY, USA | Maryland, USA | Hawaii, USA | Wisconsin, USA | Peabody, MA, USA | Maine, USA | Massachusetts, USA | North Carolina, USA | Oklahoma, USA | Ohio, USA | Indiana, USA | Louisiana, USA | Alaska, USA | Michigan, USA | Illinois, USA | Alabama, USA | Idaho, USA

Hybrid

Hybrid role; up to 20% travel.

Category
IT & Security (1)
Required Skills
Threat modeling
Vulnerability Analysis
Cryptography

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • 10+ years industry experience in Information Security
  • 8+ years experience with embedded system, IOT, or medical device cybersecurity
  • Bachelor’s degree or equivalent
  • Experience generating Threat models without the use of threat modeling tools
  • Experience performing risk assessments utilizing CVSS 3.1 or higher, with STRIDE per element
  • Ability to write technical security requirements for embedded systems and web platforms based on the latest regulations
  • Understanding and execution of third-party penetration testing, vulnerability scanning, CVSS and/or other general security testing principles
  • Experience supporting regulatory security submissions, ensuring compliance with FDA Cybersecurity Guidance (2025), EU MDR, NIST 800-53, IMDRF, and AAMI TIR57
  • Knowledge of real-time operating systems hardening techniques
  • Knowledge of cloud security principles
  • Ability to generate SBOMs from Software source code and Binaries, Firmware, and Operating Systems
  • Ability to generate pre-market risk assessments against the threat model leveraging STRIDE and post-market risk assessments via SCA SBOM scans
  • Ability to generate the security architecture views for medical devices that could include: Global System View, Multi-Patient Harm View, Updateability/Patchability view and, detailing system boundaries, data flows, and external interactions to show risk mitigation, ensuring transparency, and supporting post-market management
  • Ability to translate technical security requirements into solutions
  • Ability to provide secure coding recommendations and execute reviews
  • Data privacy experience, including HIPAA and GDPR
  • Understanding of industry standards and certifications such as HITRUST & ISO 27001
  • Ability to work autonomously and proactively seek out product security opportunities within heart recovery
  • Ability to lead large projects and proven ability to track to project plan timelines from a security perspective
  • Ability to create and deliver cybersecurity awareness campaigns and other communications
  • Customer focus (internal & external)
  • Excellent communication and collaboration skills, able to network, interface and influence at all levels of the organization, cross sector, cross-functionally and globally
  • Strong leadership skills
Responsibilities
  • Drive alignment to J&J Product Security’s overarching framework
  • Support the Product Security strategy and objectives within Heart Recovery
  • Define and implement secure boot, firmware integrity validation, and anti-tamper mechanisms to protect Heart Recovery Device firmware against unauthorized modification
  • Enforce cryptographic protocols for data-at-rest and data-in-transit, ensuring compliance with FDA cybersecurity requirements, NIST 800-175, FIPS 140-3, and IEC 62443
  • Define and implement key management infrastructure (PKI, HSMs, TPMs, and secure enclave integration) for device identity, authentication, and software signing
  • Develop real-time vulnerability assessment techniques for detecting security flaws in wireless communications (Bluetooth LE, NFC, Wi-Fi, 5G, proprietary RF) used in Heart Recovery’s medical devices
  • Implement Zero Trust security for device-to-cloud connectivity, integrating mTLS and continuous authentication models into clinical applications
  • Oversee secure OTA (over-the-air) update mechanisms, ensuring firmware rollbacks, code signing, and supply chain integrity validation
  • Embedded Security & Secure Development Lifecycle:
  • Lead Secure Development Lifecycle practices, integrating threat modeling, static/dynamic analysis, fuzz testing, and formal verification into the development process
  • Work with R&D Engineering to define hardware security architecture, including trust zones, hardware root of trust (HRoT), and secure microcontroller protections
  • Implement memory safety strategies to mitigate buffer overflows, side-channel attacks, and execution vulnerabilities in real-time operating systems (RTOS) and bare-metal firmware
  • Respond to customer cybersecurity questionnaires and contractual language for post-market medical devices under your responsibility as necessary
Desired Qualifications
  • Experience leading or participating in formal security audits
  • Experience with Operating Systems such as QNX QOS, Yocto, Linux Ubuntu. Alpine
  • Familiarity with FDA and/or other global regulatory cybersecurity guidance requirements and submission process
  • Experience with web applications and server hardening (i.e. AWS, Azure) including knowledge of OWASP Top 10 and blue teaming techniques
  • Experience in cybersecurity pre-sales
  • Software development experience
  • CISSP, CISM, or other security certification
  • MS and/or advanced degree

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • J&J's stock surged 47.1% over the past year, outperforming the healthcare sector.
  • FDA approved J&J's Dual Energy cardiac ablation platform for electrophysiology in 2026.
  • J&J's 2026 revenue will exceed $100 billion for the first time in history.

What critics are saying

  • 58,206 pending talc ovarian cancer lawsuits risk multi-billion payouts within 12–24 months.
  • Eli Lilly's obesity drugs dominate 56% of its revenue, eroding J&J's pharma growth.
  • Abiomed's Impella trial failure forces J&J's cardiovascular unit to contract by 10–15%.

What makes Johnson & Johnson unique

  • J&J uniquely spans pharmaceuticals, MedTech, and consumer health across 140 years.
  • Its Dual Energy THERMOCOOL platform delivers both radiofrequency and pulsed field energy.
  • J&J raised 2026 revenue guidance to $100.8–$101.4 billion after Q2 beat.
  • J&J's oncology portfolio gained multiple FDA approvals in early 2026.
  • MedTech growth is fueled by Shockwave (2024) and Abiomed (2022) acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.